Media Coverage
Source: Daily Journal
Media Coverage
06.24.13
San Diego-based biotech company Receptos Inc. raised $72.8 million in an initial public offering in May 2013. It will use the funding to continue its research and development of therapies for immune disorders such as multiple sclerosis and inflammatory bowel disease.
Corporate and securities technology partner Mike Hird led the Pillsbury team advising Receptos on the matter. The team included partner Richard Blaylock, counsel Patty DeGaetano and associate Matt Hallinan, and relied on support from cross-practice colleagues throughout the firm.
Pillsbury has a rich history of advising tech startups from incorporation to maturation, including CriticalPath, Magma Design, Netcom, NexGen, S3, Sirf and WebEx, all of which achieved valuations over $1 billion.